Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Tolebrutinib for Myasthenia Gravis
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial is testing a new drug, tolebrutinib, to see if it is better than a placebo at treating moderate to severe myasthenia gravis (MG). The trial will last for 2 years and will involve 7 site visits during the first 26 weeks (double-blind treatment period) and quarterly visits during the open label extension period.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.